Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's ...

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck also lowered revenue guidance for 2025. 10 stocks we like better than Merck › The stock for pharmaceutical giant Merck ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol ...

Although Merck (currently trading at $84.57 per share) has gained 7% over the last six months, it has trailed the S&P 500’s 21.3% return during that period. This may have investors wondering how to ...

Merck (MRK) stock is in focus as the company secures $700M from Blackstone to advance cancer therapy sacituzumab tirumotecan ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Last week’s earnings call didn’t deliver what Merck & Co. ($MRK) investors were hoping for. While the company posted what ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...